Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
SANTA BARBARA, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra" or the “Company”), today announced it has provided an initial response to the U.S. Food and Drug Administration (“FDA”) …